Cerella™: Reduce the time and cost of your discovery cycles with deep learning
In this webinar, we demonstrate how Cerella™ (AI drug discovery software) highlights new opportunities and guides more efficient compound optimisation.
In this webinar, we demonstrate how Cerella™ (AI drug discovery software) highlights new opportunities and guides more efficient compound optimisation.
Learn how advances in informatics technology are inspiring a new generation of innovative products that streamline and enhance the efficiency and productivity of drug discovery software.
In this webinar we demonstrated how this new platform provides interactive access to deep learning imputation to extract more value…
We presented a case study in which Alchemite was applied to a data set comprising approximately 700,000 compounds and 1,000…
In this webinar you can hear how a combination of generative chemistry and deep learning has impacted the design of…
This article outlines practical applications of deep learning on drug discovery data. It introduces some of the research behind our…
In this webinar, we explore how the limitations of pharmaceutical data can impact conventional predictive model building. Our speakers, Julian Levell (Constellation pharmaceuticals), Ben Irwin and matt Segall (Optibrium) demonstrate how the deep learning imputation algorithm underlying our Cerella platform, overcomes these challenges.
This article describes a novel deep learning neural network method and its application for the imputation of bioactivity data, such…
In European Biopharmaceutical Review, Optibrium’s CEO Dr Matthew Segall discusses how we can elevate drug discovery with deep learning imputation. He shares…
Optibrium’s QuanSA 3D-QSAR method uses an active learning approach to successfully and more efficiently identify a mimic of a macrocyclic natural product
Join Optibrium at HubXchange in Boston to hear more about implementing AI in drug discovery.
Cloud-based version of StarDrop retains all the functionality and interactivity of desktop version with improved accessibility and lower total cost of ownership for customers.
Out now in International Biopharmaceutical Industry, Optibrium’s CEO, Dr Matt Segall introduces the concept of augmented intelligence. He explains how to use dynamic…
In this ebook we demonstrate our deployable AI discovery platform, Cerella™. Browse real-world stories of success from our collaborations with AstraZeneca, Genetech, Takeda Pharmaceuticals, Constellation Pharmaceuticals and many more.
Discover the skills, knowledge and tools which are essential for success for today’s drug hunters.
Out now in Innovations in Pharmaceutical Technology, Optibrium’s Global Head of Application Science and President of Optibrium Inc, Dr Tamsin Mansley discusses…
In this ebook, you’ll discover the key considerations which every leader needs to take in order to successfully implement AI in their drug discovery pipelines.
There is no excerpt because this is a protected post.